SCHEMBL4565885

SCHEMBL4565885

CCCCC(=O)Nc1cccc(C(=O)O)c1C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SELP P16109 1/20 0.61
SELE P16581 1/20 0.61
ALDH1A1 P00352 3/20 0.57
KDM4E B2RXH2 3/20 0.57
POLB P06746 2/20 0.57
SMN1; SMN2 Q16637 3/20 0.55
CETP P11597 1/20 0.55
HDAC3 O15379 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC2 Q92769 1/20 0.54
HDAC10 Q969S8 1/20 0.54
HDAC11 Q96DB2 1/20 0.54
HDAC8 Q9BY41 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
HDAC9 Q9UKV0 1/20 0.54
HDAC5 Q9UQL6 1/20 0.54
CYP2C9 P11712 1/20 0.53
HPGD P15428 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10981533 0.94 SOAT1 (0.59) SELPSELEALDH1A1KDM4EPOLB
SCHEMBL10982243 0.94 SOAT1 (0.59) SELPSELEALDH1A1KDM4EPOLB
SCHEMBL10987960 0.94 SOAT1 (0.59) SELPSELEALDH1A1KDM4EPOLB
SCHEMBL9532980 0.86 CYP2C9 (0.69) ALDH1A1KDM4EPOLBSMN1; SMN2CETP
SCHEMBL23748613 0.86 KDM4E (0.60) ALDH1A1KDM4EPOLBSMN1; SMN2CETP
SCHEMBL9958894 0.84 ALDH1A1 (0.60) SELPSELEALDH1A1KDM4EPOLB
SCHEMBL7440627 0.82 SELP (0.52) SELPSELEALDH1A1KDM4EPOLB
SCHEMBL7636178 0.81 SOAT1 (0.68) ALDH1A1KDM4EPOLBSMN1; SMN2CETP
SCHEMBL5840193 0.81 SOAT1 (0.68) ALDH1A1KDM4EPOLBSMN1; SMN2CETP
SCHEMBL7634493 0.81 SOAT1 (0.68) ALDH1A1KDM4EPOLBSMN1; SMN2CETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473249-B2 Aromatic compounds and pharmaceutical uses thereof BASF AS (NO) 2025-11-18 US disclosed
US-20210380521-A1 AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF BASF AS (NO) 2021-12-09 US disclosed
US-20210380521-A1 AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF BASF AS (NO) 2021-12-09 US disclosed
EP-3864001-A1 ROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF BASF AS (NO) 2021-08-18 EP disclosed
CN-113166024-A Aromatic compounds and their medical use 巴斯夫股份公司 2021-07-23 CN disclosed
EP-2132187-A2 DUAL-ACTING ANTIHYPERTENSIVE AGENTS Theravance, Inc. (US) 2009-12-16 EP disclosed
WO-2008097459-A2 DUAL-ACTING ANTIHYPERTENSIVE AGENTS THERAVANCE, INC. (US) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12473249-B2 Aromatic compounds and pharmaceutical uses thereof GLS2, FFAR3, SLC10A1 SELP 1917/4885SELE 3096/4885ALDH1A1 530/4885
US-20210380521-A1 AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF GLS2, FFAR3, SLC10A1 SELP 1917/4885SELE 3096/4885ALDH1A1 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.